- Home
- INV vs CTNM Comparison
INV vs CTNM Comparison
Compare INV & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- CTNM
- Stock Information
- Founded
- INV 2015
- CTNM 2009
- Country
- INV United States
- CTNM United States
- Employees
- INV N/A
- CTNM N/A
- Industry
- INV
- CTNM
- Sector
- INV
- CTNM
- Exchange
- INV NYSE
- CTNM Nasdaq
- Market Cap
- INV 448.7M
- CTNM 453.0M
- IPO Year
- INV N/A
- CTNM 2024
- Fundamental
- Price
- INV $10.66
- CTNM $14.34
- Analyst Decision
- INV
- CTNM Strong Buy
- Analyst Count
- INV 0
- CTNM 4
- Target Price
- INV N/A
- CTNM $29.25
- AVG Volume (30 Days)
- INV 19.2K
- CTNM 78.5K
- Earning Date
- INV 11-14-2024
- CTNM 11-06-2024
- Dividend Yield
- INV N/A
- CTNM N/A
- EPS Growth
- INV N/A
- CTNM N/A
- EPS
- INV N/A
- CTNM N/A
- Revenue
- INV $988,000.00
- CTNM N/A
- Revenue This Year
- INV N/A
- CTNM N/A
- Revenue Next Year
- INV N/A
- CTNM N/A
- P/E Ratio
- INV N/A
- CTNM N/A
- Revenue Growth
- INV 4.88
- CTNM N/A
- 52 Week Low
- INV $8.55
- CTNM $12.33
- 52 Week High
- INV $18.75
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- INV N/A
- CTNM N/A
- Support Level
- INV N/A
- CTNM N/A
- Resistance Level
- INV N/A
- CTNM N/A
- Average True Range (ATR)
- INV 0.00
- CTNM 0.00
- MACD
- INV 0.00
- CTNM 0.00
- Stochastic Oscillator
- INV 0.00
- CTNM 0.00
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.